17-N-Allylamino-17-demethoxygeldanamycin

17-N-Allylamino-17-demethoxygeldanamycin
File:17-N-Allylamino-17-demethoxygeldanamycin.svg
IUPAC name [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-21- (allylamino)-6-hydroxy-5,11-dimethoxy-3, 7,9,15-tetramethyl-16,20,22-trioxo-17- azabicyclo[16.3.1]docosa-8,12,14,18,21- pentaen-10-yl] carbamate
style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers
CAS number	75747-14-7
PubChem	6440175
ChemSpider	21106220
SMILES
InChI
InChI key	AYUNIORJHRXIBJ-TXHRRWQRBY
style="background: #F8EABA; text-align: center;" colspan="2" | Properties
Molecular formula	C31H43N3O8
Molar mass	585.689 g/mol
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references

17-N-Allylamino-17-demethoxygeldanamycin is a substance that is being studied in the treatment of cancer, specific young patients with certain types of leukemia or solid tumors, especially kidney tumors. It works by targeting Hsp90, which is expressed in those tumors. As of June 2005, 17-N-allylamino-17-demethoxygeldanamycin is undergoing Phase 1 and Phase 2 clinical trials. It belongs to the family of drugs called antitumor antibiotics.

External links

• Phase 1 trial
• Another Phase 1 trial
• National Cancer Institutie Bulletin on Phase 2 trials against Von Hippel-Lindau disease
• Safety sheet for 17AAG